Biospecifics Technologies Corp Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Biospecifics Technologies Corp (NASDAQ: BSTC) today and set a price target of $65. The company’s shares closed yesterday at $42.69.

According to TipRanks.com, Selvaraju is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -4.5% and a 38.2% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, EyePoint Pharmaceuticals Inc, and Synergy Pharmaceuticals Inc.

Biospecifics Technologies Corp has an analyst consensus of Moderate Buy, with a price target consensus of $65.

See today’s analyst top recommended stocks >>

Based on Biospecifics Technologies Corp’s latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of $3.98 million. In comparison, last year the company had a net profit of $3.34 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioSpecifics Technologies Corp. engages in the development of an injectable collagenase for multiple indications. Its product includes XIAFLEX, is an injectable collagenase enzyme, which is used for the treatment of Dupuytren’s contracture in adults with a palpable cord in the palm. The company was founded in 1990 and is headquartered in Lynbrook, NY.